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Abstract Over the years, the mitochondrial fatty acid β-
oxidation (FAO) pathway has been characterised at the
biochemical level as well as the molecular biological level.
FAO plays a pivotal role in energy homoeostasis, but it
competes with glucose as the primary oxidative substrate.
The mechanisms behind this so-called glucose–fatty acid
cycle operate at the hormonal, transcriptional and biochem-
ical levels. Inherited defects for most of the FAO enzymes
have been identified and characterised and are currently
included in neonatal screening programmes. Symptoms
range from hypoketotic hypoglycaemia to skeletal and
cardiac myopathies. The pathophysiology of these diseases
is still not completely understood, hampering optimal
treatment. Studies of patients and mouse models will
contribute to our understanding of the pathogenesis and
will ultimately lead to better treatment.
Abbreviations
FAO mitochondrial fatty acid β-oxidation
CPT carnitine palmitoyltransferase
MCAD medium chain acyl-coenzyme A (CoA)
dehydrogenase
CACT carnitine acylcarnitine translocase
(V)LCAD (very) long chain acyl-CoA dehydrogenase
MTP mitochondrial trifunctional protein
LCHAD long chain hydroxyacyl-CoA
dehydrogenase
SCAD short chain acyl-CoA dehydrogenase
OCTN organic cation transporter
DCI dodecenoyl-CoA delta isomerase
DECR 2,4-dienoyl CoA reductase
M/SCHAD medium and short chain hydroxyacyl-CoA
dehydrogenase
Introduction
Glucose, fatty acids and amino acids are the three substrates
an organism can use to maintain metabolic homoeostasis.
They are required for the generation of energy, but also as
building blocks for the biosynthesis of (macro)molecules.
The prime pathway for the degradation of fatty acids is
mitochondrial fatty acid β-oxidation (FAO) (Bartlett and
Eaton 2004). FAO is a key metabolic pathway for energy
homoeostasis in organs such as the liver, heart and skeletal
muscle. During fasting, when glucose supply becomes
limited, FAO is of particular importance. Under this
condition, most tissues, except the brain, can use fatty
acids directly to generate energy. Furthermore, the liver
converts fatty acids into ketone bodies, a process for which
FAO is indispensable. Ketone bodies serve as an additional
energy source that is used by all tissues including the brain.
In this review, we sketch a historical perspective of FAO
research and introduce different aspects of the topic.
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Georg Franz Knoop discovered fatty acid β-oxidation. In
1904, he published his classical experiments using odd and
even chain ω-phenyl fatty acids such as ω-phenylvaleric
acid and ω-phenylbutyric acid (Knoop 1904). Knoop fed
these compounds to dogs and analysed their urine. In dogs
that had been fed the odd chain fatty acids, he found
hippuric acid (conjugate of benzoic acid and glycine),
whereas, the dogs that had been fed even chain fatty acids
excreted phenaceturic acid (conjugate of phenylacetic acid
and glycine). From this he concluded that the metabolism
of fatty acids proceeds by the successive removal of two
carbon fragments. The remaining fatty chain had to contain
a carboxylic acid. He postulated that oxidation took place
on the β carbon atom, an oxidation unknown to organic
chemistry. Henry Drysdale Dakin confirmed and further
developed the β-oxidation theory of Knoop, also by using
phenyl derivatives of fatty acids (Dakin 1908). Another
landmark was Irving B. Fritz’s discovery of the stimulation
of FAO by carnitine (Fritz 1955; Fritz and McEwen 1959).
The first inherited defects in the FAO pathway were
identified in the 1970s, carnitine palmitoyltransferase 2
(CPT2) deficiency in 1973, primary carnitine deficiency in
1975 and medium chain acyl-coenzyme A (CoA) dehydro-
genase (MCAD) deficiency in 1976 (DiMauro and
DiMauro 1973; Karpati et al. 1975; Gregersen et al.
1976). Most FAO enzymes were purified in the 1980s
(Furuta et al. 1981), followed by the cloning of the
individual genes and the subsequent identification of
disease-causing mutations in patients (Kelly et al. 1990;
Yokota et al. 1990; Matsubara et al. 1990).
Biochemical basis of fatty acid oxidation
Transport across the plasma membrane and fatty acid
activation
Mitochondria, as well as peroxisomes, harbour all enzymes
necessary for FAO. Mitochondria are the main site for the
oxidation of plasma free fatty acids or lipoprotein-
associated triglycerides. This implies that several transport
steps are necessary before fatty acids are oxidised.
Triglycerides are first hydrolysed by the action of
endothelium-bound lipoprotein lipase. The uptake of fatty
acids seems to be largely mediated by membrane proteins,
although passive uptake probably also occurs.
Fatty acid transport proteins (FATPs) are integral
transmembrane proteins that enhance the uptake of long
chain and very long chain fatty acids into cells. In humans,
FATPs comprise a family of six highly homologous
proteins, FATP1–FATP6, which are found in all fatty acid-
utilising tissues of the body (Doege and Stahl 2006). FATPs
have acyl-CoA synthetase activity, suggesting that fatty
acids are rapidly converted to acyl-CoAs after translocation
across the plasma membrane, a process that may drive the
transport. Skeletal muscle expresses FATP1 (SCL27A1) and
FATP4 (SCL27A4), whereas heart specifically expresses
FATP6 (SCL27A6) as well as FATP1 (Gimeno et al. 2003).
In liver, FATP5 (SCL27A5) plays a crucial role in the
hepatocellular uptake of fatty acids (Doege et al. 2006).
Interestingly, there is a second protein sub-family with long
chain acyl-CoA synthetase activity, the long-chain acyl-
CoA synthetases (ACSL) (Soupene and Kuypers 2008),
illustrating that fatty acid activation is a complex process.
Besides FATPs, plasma membrane fatty acid-binding
protein (FABPpm, which is identical to mitochondrial
aspartate aminotransferase, gene name GOT2), and fatty
acid translocase (FAT, CD36) are involved in the uptake of
fatty acids (Glatz et al. 2006; Kiens 2006).
In order to maintain high rates of FAO in liver, heart and
skeletal muscle, cytoplasmic fatty acid-binding proteins
(FABPs) are required (Schaap et al. 1999; Binas et al. 2003;
Erol et al. 2004). There are many tissue-specific FABPs.
Liver FABP is encoded by the FABP1 gene. Heart and
skeletal muscle express heart type FABP (FABP3).
The carnitine shuttle
The mitochondrial membrane is impermeable to acyl-CoAs.
For their import into mitochondria, acyl-CoAs use the
carnitine shuttle (Fig. 1). The first step of this shuttle is
performed by CPT1, which converts an acyl-CoA into an
acylcarnitine. There are two isoforms that are important for
FAO. CPT1A (gene CPT1A), also called liver CPT1, is not
only expressed in the liver, but also in the brain, kidney,
lung, spleen, intestine, pancreas, ovary and fibroblasts.
CPT1B (gene CPT1B) is the muscle isoform that is highly
expressed in heart, skeletal muscle and testis. Both proteins
are present at the outer mitochondrial membrane and are
sensitive to inhibition by malonyl-CoA. Carnitine acylcar-
nitine translocase (CACT, SLC25A20) exchanges acylcar-
nitines for a free carnitine molecule from the inside. Once
the acylcarnitines have entered the mitochondria, CPT2
(gene CPT2), located at the mitochondrial inner membrane,
reconverts the acylcarnitines into their CoA esters, which
can then undergo FAO (van der Leij et al. 2000; Ramsay et
al. 2001; Bonnefont et al. 2004). CPT1C is a brain-specific
CPT with a currently unknown function (Price et al. 2002).
Both CPT1 and CPT2 are primarily involved in the import
of (dietary) long-chain acyl-CoAs, such as palmitoyl-CoA,
oleoyl-CoA, and linoleoyl-CoA.
Alternatively, carnitine can be converted in the mito-
chondrial matrix into an acylcarnitine by the action of
CPT2 or carnitine acetyl transferase (CAT, gene CRAT).
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also in the opposite direction via CACT, resulting in the
transport of these acylcarnitines into the cytosol. Acylcar-
nitines can also cross the plasma membrane, but the
mechanism is currently unknown. After crossing the plasma
membrane, acylcarnitines are excreted from the body via
either urine or bile. This detoxification mechanism is
especially important when acyl-CoAs accumulate; for
example, in disorders of mitochondrial FAO. Recently this
pathway has been proposed to play a role in the
pathogenesis of type 2 diabetes and insulin resistance.
These conditions are characterised by a metabolic overload
of mitochondria with fatty acids, which is reflected by
increased levels of plasma acylcarnitines and decreased free
carnitine levels. The elevation of free carnitine and, thereby,
promotion of the export of acylcarnitines is proposed as a
novel therapeutic approach (Koves et al. 2008; Noland et
al. 2009; Mynatt 2009; Adams et al. 2009). For the
maintenance of carnitine homoeostasis, plasma carnitine
can be taken up by tissues via the carnitine transporter,
organic cation transporter 2 (gene OCTN2).
The β-oxidation cycle
Once inside the mitochondria, acyl-CoAs are degraded into
acetyl-CoA units via the classic series of four enzyme
reactions called β-oxidation (Fig. 1). The β-oxidation
pathway is a cyclic process in which acyl-CoAs are
shortened, whereby the two carboxy-terminal carbon atoms
are released as acetyl-CoA units each time a cycle is fully
completed. First, an acyl-CoA-ester is dehydrogenated to
yield a trans-2-enoyl-CoA. This is followed by hydration
of the double bond. In the third step the resulting L-3-
hydroxy-acyl-CoA is dehydrogenated to 3-keto-acyl-
CoA. Finally, thiolytic cleavage of the 3-keto-acyl-CoA
produces a two-carbon chain-shortened acyl-CoA plus
acetyl-CoA. Each cycle yields an acyl-CoA shortened by
two carbon atoms, an acetyl-CoA, and one nicotinamide
adenine dinucleotide (NADH) and one flavin adenine
dinucleotide (FADH2) as electron carriers (or reducing
equivalents). The resulting acyl-CoA enters another cycle
of FAO; the acetyl-CoA can enter the citric acid cycle and
the electron carriers deliver the electrons to the electron
transport chain.
Directly after import, the long chain acyl-CoAs are
metabolised first by the membrane-bound enzymes, very
long chain acyl-CoA dehydrogenase (VLCAD, encoded by
ACADVL) and mitochondrial trifunctional protein (MTP,
encoded by HADHA and HADHB), which has hydratase,
long chain hydroxyacyl-CoA dehydrogenase (LCHAD) and
thiolase activity. After 2–3 FAO cycles using these
enzymes, the resulting medium acyl-CoAs are metabolised
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Fig. 1 Mitochondrial fatty acid β-oxidation in humans a and in the
mouse b. After transport across the plasma membrane, fatty acids are
activated to acyl-CoAs at the cytosolic site. CPT1 converts the acyl-
CoA into an acylcarnitine, which is subsequently transported across
the mitochondrial membrane by CACT. CPT2 converts the acylcarni-
tine back into an acyl-CoA. Long chain acyl-CoAs are metabolised by
the membrane bound enzymes, very long chain acyl-CoA dehydroge-
nase (VLCAD) and mitochondrial trifunctional protein (MTP), which
has hydratase, long chain hydroxyacyl-CoA dehydrogenase (LCHAD)
and thiolase activity. Short and medium chain acyl-CoAs are
metabolised in the mitochondrial matrix by medium chain acyl-CoA
dehydrogenase (MCAD), short chain acyl-CoA dehydrogenase
(SCAD), crotonase, medium and short chain hydroxyacyl-CoA
dehydrogenase (M/SCHAD) and medium chain 3-ketoacyl-CoA
thiolase (MCKAT). The oxidation of unsaturated fatty acids such as
oleic acid requires the action of an isomerase [dodecenoyl-CoA delta
isomerase (DCI)]. C18 denotes an acyl-CoA with a chain length of 18
carbon atoms, and so forth
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MCAD (encoded by ACADM) and, after another 3–4F A O
cycles, short chain acyl-CoA dehydrogenase (SCAD,
encoded by ACADS) participates in the final 1–2 cycles.
For the second, third and fourth steps of FAO of medium
and short chain acyl-CoAs, there is one set of three distinct
matrix-soluble enzymes: the enoyl-CoA hydratase called
crotonase (encoded by ECHS1), the medium and short
chain hydroxyacyl-CoA dehydrogenase (M/SCHAD,
encoded by HADH) and medium chain 3-ketoacyl-CoA
thiolase (MCKAT, encoded by ACAA2). All have broad
substrate specificity towards CoA-esters with chain lengths
of up to ten carbon atoms. The oxidation of mono-
unsaturated fatty acids such as oleic acid requires the
action of dodecenoyl-CoA delta isomerase (3,2 trans-enoyl-
CoA isomerase, encoded by DCI). Polyunsaturated fatty
acids need a second auxiliary enzyme, 2,4-dienoyl CoA
reductase 1 (DECR1). The FAO pathway as described
above is displayed in Fig. 1.
An acyl-coenzyme A dehydrogenase (ACAD) enzyme
performs the first step of each FAO cycle. ACAD enzymes
have several interesting aspects. First, they have tightly
bound FAD as a prosthetic group. The reduced flavopro-
teins are re-oxidised by electron transfer flavoprotein
(ETF). ETF is a heterodimer consisting of two flavopro-
teins, the α and β subunits (ETFA and ATFB). The reducing
equivalents are subsequently transferred to ETF dehydro-
genase (ETFDH), another flavoprotein that feeds the
electrons into the respiratory chain via ubiquinone. Second,
whereas there seems to be only one membrane-associated
enzyme system and one matrix localised enzyme system for
the second, third and fourth FAO steps, five different
ACAD enzymes may catalyse the first step in FAO.
VLCAD is specific for long chain acyl-CoAs, whereas
LCAD has broad substrate specificity and is active with
medium and long chain acyl-CoAs. Apart from straight-
chain substrates, LCAD has been shown to catalyse the
degradation of branched-chain acyl-CoAs and certain mono-
unsaturated and polyunsaturated acyl-CoAs (Wanders et al.
1998;L ee ta l .2000; Chegary et al. 2009). In contrast to the
membrane-associated VLCAD, LCAD is present in the
mitochondrial matrix. In humans, LCAD does not seem to
play a prominent role in FAO, due to the extremely low
expression levels (Chegary et al. 2009). In rodents, however,
LCAD plays a significant role in FAO, as evidenced by the
phenotype of LCAD
−/− mice (Fig. 1a,b (Kurtz et al. 1998;
Cox et al. 2001; Chegary et al. 2009)). ACAD9 is a second
enzyme associated with the mitochondrial inner membrane
that is able to dehydrogenate long chain acyl-CoAs (Zhang
et al. 2002; Ensenauer et al. 2005). Its exact function in FAO
remains to be elucidated, despite the recent description of
three patients suggested to suffer from ACAD9-deficiency
(He et al. 2007). Medium and short chain acyl-CoAs are
handled by MCAD and SCAD, respectively, that reside in
the matrix.
Regulation of fatty acid oxidation and substrate use
in energy homoeostasis
Organs are flexible in the choice of which substrate they
will use to maintain energy homoeostasis. Under normal,
well-fed conditions, glucose will be the preferred substrate
for oxidation. During fasting, however, fatty acids and
ketone bodies will become a more important energy source
as an alternative to glucose. This reciprocal relationship or
competition between the oxidation of fatty acids and
glucose is also known as the glucose–fatty acid or Randle
cycle. A general explanation for the occurrence of this cycle
is the glucose-sparing effect of FAO and ketone body
utilisation. Thus, glucose can be saved for use in the brain
when nutritional sources of glucose are scarce. In muscle,
the situation is more complex. During exercise, the choice
of substrate is determined by exercise intensity and duration.
Glucose utilisation increases as exercise intensity increases.
In contrast, FAO is already maximal at moderate exercise
intensity (Helge et al. 2007). In the heart, the situation is
also exceptional. FAO is extremely important for this organ,
since it constantly relies on fatty acids for a major proportion
(60–90%) of its energy needs (Schulz 1994).
There are several mechanisms for the regulation of
cellular substrate use. We briefly describe these levels of
regulation, but, for an in depth description of these and
other mechanisms, the reader is referred to a recent
excellent review (Hue and Taegtmeyer 2009). An important
driver in substrate use is substrate availability. Hormones
are crucial players at this level. Insulin is secreted by the
pancreatic β-cells when blood glucose levels are high. One
of the main effects of insulin is the increase of glucose
transport by translocation of the glucose transporter Glut4
(SLC2A4) from intracellular vesicles to the plasma mem-
brane. Insulin also inhibits lipolysis, and thus prevents the
availability of its competing substrate fatty acid. On the
other hand, during fasting or exercise, the hormones
adrenalin, noradrenaline, glucagon and adrenocorticotropic
hormone (ACTH) induce lipolysis by stimulating hormone-
sensitive lipase activity in the adipose tissue. This leads to
the release of free fatty acids into the circulation.
Metabolites can also affect the transcriptional regulation
of genes involved in metabolism such as enzymes. For
example, free fatty acids are activating ligands for perox-
isome proliferator-activated receptors [PPARs (Krey et al.
1997; Forman et al. 1997; Murakami et al. 1999; Xu et al.
1999)], a subclass of the nuclear hormone receptor family.
Nuclear hormone receptors typically consist of a DNA-
binding domain and a ligand-binding domain. The DNA-
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elements in the promoter of target genes. Upon ligand
binding, nuclear receptors (NRs) undergo a conformation
change, which induces dissociation of co-repressors and the
recruitment of transcriptional cofactors, resulting in tran-
scription activation. This property makes NRs on the one
hand interesting pharmaceutical targets and on the other
hand potential mediators in the pathology of disorders in
which potential ligands accumulate. Activation of PPARα
and PPARβ by (dietary) fatty acids such as oleic acid
makes tissues more dependent on FAO, by stimulating
cellular fatty acid utilisation pathways including transport,
esterification, and oxidation (Mandard et al. 2004).
Effects on transcriptional regulation are often long-term
adaptations. Several mechanisms exist for the short-term
regulation of substrate use. The activity of specific enzymes
such as pyruvate dehydrogenase (PDH), phosphofructoki-
nase and CPT1, is controlled by metabolites (Hue and
Taegtmeyer 2009).
CPT1 catalyses one of the rate-limiting steps in FAO
(Drynan et al. 1996). CPT1 activity is regulated by its
inhibitor: malonyl-CoA. The cellular energy status is one of
the regulators of malonyl-CoA production. During energy
shortage, adenosine triphosphate (ATP) levels fall and
adenosine monophosphate levels (AMP) rise, resulting in
the activation of AMP-activated protein kinase (AMPK).
Activated AMPK initiates a signalling cascade aimed to
restore cellular energy levels. A principal event is the
phosphorylation of acetyl-CoA carboxylase (ACC), the
enzyme that converts acetyl-CoA in malonyl-CoA. Thus,
AMPK activation aims to increase energy production by
FAO.
PDH catalyses the oxidative decarboxylation of pyruvate
to acetyl-CoA and links glycolysis with oxidative metabo-
lism. The reaction is irreversible and, therefore, well
controlled. The main regulation occurs by reversible
phosphorylation of PDH, which abolishes enzyme activity.
The PDH complex contains associated regulatory enzymes,
including pyruvate dehydrogenase kinase (PDK) and
pyruvate dehydrogenase phosphatase. The activities of
these enzymes determine the proportion of PDH in its
active dephosphorylated state. The activity of PDK is
regulated by short- and long-term mechanisms. Short-term
regulation includes activation of PDK by the reaction
products of PDH, i.e. acetyl-CoA and NADH. Thus, high
acetyl-CoA/CoA and NADH/NAD
+ ratios activate PDK,
leading to inhibitory phosphorylation of PDH. The sub-
strate of PDH, i.e. pyruvate, inhibits PDK activity. Long-
term regulation of PDK activity occurs primarily at the
transcriptional level. For example, PPARs stimulate the
transcription of PDK4 (Wu et al. 2001; Huang et al. 2002),
an effect that can be potentiated by the activation of AMPK
(Houten et al. 2009).
FAO deficiencies
For almost each enzyme involved in FAO, inherited defects
have been described (Wanders et al. 1999; Rinaldo et al.
2002). These include glutaric aciduria type 2, primary
carnitine deficiency and deficiencies of CPT1a, CACT,
CPT2, VLCAD, MTP (including isolated LCHAD or
thiolase), MCAD, M/SCHAD, SCAD and 2,4-dienoyl
CoA reductase (DECR). Interestingly, CPT1b, crotonase,
MCKAT and DCI deficiency have not been identified as of
yet.
In general, FAO defects have three different presentations
(Wanders et al. 1999; Rinaldo et al. 2002). The first is the
hepatic presentation, which is a severe, often lethal, disease
in infancy or the neonatal period with hypoketotic hypo-
glycaemia and Reye-like syndrome. This disease is triggered
by a catabolic state, for example during intercurrent
infections. Most importantly, this condition can be pre-
vented, which is the main reason for the inclusion of FAO
defects in neonatal screening programmes. During infancy,
patients may also present with cardiac symptoms such as
dilated or hypertrophic cardiomyopathy and/or arrhythmias.
Alternatively, FAO defects might present as a milder, later
(‘adult’) onset disease. This form is characterised by
exercise-induced myopathy and rhabdomyolysis. Severely
affected patients may display combinations of all three
presentations. In addition, FAO defects have been associated
with sudden infant death that may have been caused by
hypoketotic hypoglycaemia or cardiac disease.
Cardiac presentation and muscular signs in FAO defects
The cardiac presentation and muscular signs in FAO defects
have been documented in a group of 107 patients (89
families) with an FAO defect (Saudubray et al. 1999;
Bonnet et al. 1999). Table 1 summarises the data from this
paper. Cardiac involvement and/or muscular signs have
never been described in CPT1a and MCAD deficiency. For
CPT1a deficiency, this is probably explained by the specific
expression of CPT1b in heart and skeletal muscle. For
MCAD deficiency, there are two likely explanations. First,
energy generation by the FAO pathway is not completely
impaired in these patients. Second, medium chain acylcar-
nitines may be less toxic than long chain acylcarnitines.
This explains why MCAD-deficient patients can be
completely asymptomatic. The disease presents itself
usually as hypoketotic hypoglycaemia triggered by pro-
longed fasting during intercurrent infections. If one leaves
these patients and a corresponding proportion of patients
with an unknown defect out of this group (87 patients),
63% of the patients have a cardiac presentation and 51%
have muscular signs.
J Inherit Metab Dis (2010) 33:469–477 473Of interest is the high frequency of heart beat disorders in
patients with long chain FAO defects [Table 1,( S a u d u b r a ye t
al. 1999; Bonnet et al. 1999)]. Often, this is without
cardiomyopathy. These include conduction abnormalities
such as left bundle-branch block, atrioventricular block and
sinus node dysfunction, and arrhythmias such as ventricular
tachycardia, ventricular fibrillation and supraventricular
tachycardia. Bonnet et al. suggested that FAO deficiencies
should be considered in unexplained sudden infant death or
collapse in infants, but also in infants with conduction
defects or ventricular tachycardia (Bonnet et al. 1999).
Pathophysiology of FAO defects
So far, the exact pathogenetic mechanisms leading to hypo-
glycaemia in FAO defects have only partially been elucidated.
Two different explanations are likely: increased use of glucose
and/or decreased glucose production. FAO is able to stimulate
gluconeogenesis (GNG) in vitro (Williamson et al. 1966)a s
well as in vivo (Fanelli et al. 1993). In accordance with this
notion, inhibitors of FAO abolished the stimulation of GNG
by FAO (Williamson et al. 1968). This effect was mediated by
pyruvate carboxylase, the rate-limiting enzyme of GNG,
which has an absolute requirement for acetyl-CoA as cofactor
(Utter and Keech 1963; Scrutton and Utter 1967). Low acetyl-
CoA levels due to a FAO defect could limit GNG.
On the other hand, patients with an FAO defect will
generate less energy from fatty acids and ketones. Given the
glucose–fatty acid cycle (see above), glucose use will be
increased. Fuel metabolism has been assessed in patients with
CPT2 and VLCAD deficiency (Orngreen et al. 2004, 2005).
These patients had normal FAO at rest, but prolonged low
intensity exercise revealed impaired FAO and a high
respiratory exchange ratio, indicating that the defect in
FAO was compensated for by increased carbohydrate
metabolism, in this case enhanced muscle glycogenolysis
(Orngreen et al. 2004, 2005).
To explain the pathogenesis of muscle disease in FAO
defects, two hypotheses seem likely. First, energy shortage
due to the FAO defect may be the primary event leading to
disease. Alternatively, accumulation of metabolites could
cause the myopathies. Of course, a combination of both
disease mechanisms is equally possible.
Rhabdomyolysis The pathophysiology of rhabdomyolysis
is heterogeneous and, in some cases, not completely
understood. In general, it seems likely that the cause lies
in the breakdown of sodium/calcium homoeostasis in the
muscle cell (Huerta-Alardin et al. 2005). ATP depletion due
to the FAO defect could lead to insufficient function of the
sodium/potassium ATPase, the calcium ATPase and the
calcium/sodium exchanger (Warren et al. 2002; Huerta-
Alardin et al. 2005). Alternatively, accumulation of FAO
intermediates could cause increased ion leakage. The final
common effector pathway is thought to be an increase in
free cytosolic Ca
2+, which may start a cascade of effects
leading to major cell permeability and capillary leakage.
Table 1 Cardiac presentation and muscular signs in 107 patients with an FAO defect
Cardiac presentations 55/107 (51%) All but CPT1a and MCAD
Cardiomyopathy 37/55 (67%) All but CPT1a and MCAD
● Hypertrophic ● 22/37 (60%) All but OCTN2
● Dilated ● 10/37 (27%) OCTN2, MTP
● Unknown ● 5/37 (13%)
Heart beat disorders 26/55 (47%) All but CPT1a, OCTN2 and MCAD
● Without cardiomyopathy ● 14/26 (54%)
● Conduction abnormalities ● 10/26 (40%)
● Arrhythmias ● 21/26 (80%)
Collapse 17/55 (31%) All but CPT1a, OCTN2 and MCAD
● With near-miss (respiratory arrest) ● 7/17 (40%)
Muscular signs 44/107 (41%) All but CPT1a and MCAD
Myalgia, myolysis, paroxystic myoglobinuria, elevated CK 28/44 (64%) CPT2, CACT, MTP, VLCAD, LCHAD, GA2, SCHAD
Severe muscular hypotonia with respiratory distress (neonatal) 5/44 (11%) MTP
Progressive proximal myopathy 13/44 (29%) OCTN2, MTP, LCHAD, VLCAD
Patient groups included: ten OCTN2, nine CPT1a, ten CACT, 15 CPT2, 12 VLCAD, five MTP, ten LCHAD, nine MCAD, 15 GA2, and 12
unknown. Data reproduced from Saudubray et al. (1999)
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important for the heart. This is illustrated by the fact that
the heart constantly relies on fatty acids for a major
proportion (60–90%) of its energy needs. Depending on
the feeding status, glucose, lactate and ketone bodies are
used as important alternative fuels. One important issue that
has not been resolved is the question of whether oxidation
of these substrates can fully compensate for the FAO defect.
It is, however, clear that metabolic flexibility is very
important for the heart. For example, type 2 diabetes
patients are also at risk of developing cardiomyopathy. This
coincides with increased cardiac reliance on fatty acids as
the primary energy source, subsequent to the increased
circulating free fatty acid levels (Huss and Kelly 2005).
There are also numerous genetic mouse models in which
cardiac substrate use has been modulated. In general, this
leads to cardiomyopathy. It is not clear how a decrease in
metabolic flexibility leads to cardiomyopathy. Moreover, it
is not known if any of the accumulating metabolites in FAO
defects are toxic to the heart, although acylcarnitines and
fatty acids have been suggested to contribute to arrhythmias
(Corr et al. 1989; Huang et al. 1992). This could provide an
explanation for the heart-beat disorders in FAO defects and
the defect in Ca
2+ homoeostasis in the VLCAD
−/− mouse
(Bonnet et al. 1999; Werdich et al. 2007).
Mouse models for study of the pathogenesis of FAO
defects
Several mouse models with defects in FAO have been
reported. Two of these models are spontaneous mutants (jvs
and SCAD); the other models have been created by genetic
manipulation. Table 2 shows the mouse models and a
comparison of the human disease with the mouse phenotype.
With the exception of the different ACAD deficiencies, these
knockout (KO) mouse models have severe or lethal
phenotypes. This may be expected when one considers the
severe (neonatal) disease presentation in humans, which is
often caused by mutations that completely inactivate the
enzyme or prevent its correct synthesis. The relatively mild
phenotype of the VLCAD
−/− mice is unexpected. In humans,
VLCAD deficiency is a severe disease, whereas, in mice,
there is only a mild phenotype. The VLCAD
−/− mouse has
mild hepatic steatosis and mild fatty change in the heart in
response to fasting or cold (Cox et al. 2001;E x i le ta l .2003).
Exil et al. further characterised the VLCAD
−/− hearts and
demonstrated microvesicular lipid accumulation, marked
mitochondrial proliferation, and facilitated induction of
polymorphic ventricular tachycardia, without preceding
stress (Exil et al. 2006). The LCAD
−/− mouse has a more
severe phenotype, more closely resembling that of human
VLCAD deficiency. Characteristics include reduced fasting
tolerance accompanied by tissue lipidosis, hypoglycaemia
and signs of cardiomyopathy (Kurtz et al. 1998; Cox et al.
2001, 2009). In humans, LCAD deficiency has not been
identified. This remarkable difference is most likely
explained by LCAD expression levels. In humans, LCAD
expression is very low in all organs studied, but, in mice
(and rats), LCAD is expressed at levels comparable to those
of VLCAD. Thus, LCAD can take over the function of
VLCAD and vice versa, but the role of LCAD is somewhat
more prominent, making the LCAD KO the most useful
model (Chegary et al. 2009).
Conclusion
Many biochemical and genetic aspects of FAO and its
deficiencies have been addressed by recent and past
research. The exact pathophysiological mechanisms that
cause the different disease presentations are still poorly
defined, hampering the design of rational therapeutic
Disease Human
deficiency
Mouse model Reference
OCTN2 / Primary
carnitine deficiency
+ + Koizumi et al. 1988; Kuwajima et al.
1991
CPT1a + † Nyman et al. 2005
CPT1b ? † Ji et al. 2008
LCHAD / MTP ++ ++ Ibdah et al. 2001
VLCAD ++ +/− Cox et al. 2001; Exil et al. 2003
LCAD ? + Kurtz et al. 1998
MCAD −(++) +/− Tolwani et al. 2005
SCAD −(?) +/− Wood et al. 1989; Schiffer et al. 1989
DCI ? +/− Janssen and Stoffel 2002
DECR ++ (?) +/− Miinalainen et al. 2009
Table 2 Comparison of human
FAO deficiencies with those of
the available mouse models
† Embryonic lethal
? Unknown
− No phenotype or
asymptomatic
+/− Mild, + moderate, ++ severe
J Inherit Metab Dis (2010) 33:469–477 475strategies. Although feasible, studies of patients are difficult
for many reasons. Detailed studies using mouse models will
undoubtedly contribute to a better understanding of disease
pathogenesis.
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